To the scientific world, Moderna's cancer vaccine's results proved that a highly personalized, immune-targeting medication can work. To investors, it didn't work well enough.

The company's stock dropped after details of a study raised questions about how widely the treatment would be used.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。